The Biogen/Dayra partnership is driven by the strategic potential of oral macrocyclic peptides. This emerging therapeutic approach aims to deliver biologic-like efficacy and safety in a convenient ...

Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral format Collaboration further advances Biogen’s immunology strategy by broadening its ...

Egyptian Fintech firm Dayra has reportedly joined Y Combinator and has also acquired $3M in pre-seed funding. Dayra is a Cairo-headquartered Fintech company offering modern financial services to the ...

- Startup emerges from Versant’s Frontier Discovery Engine with over $70 million in capital to develop oral macrocyclic peptides - Biogen and Dayra partnership will identify, validate and optimize ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. The biopharma has paid $50 ...

Biogen (BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in immunological conditions. Macrocyclic peptides have a ...

Collaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology ...

Biogen has formed a research collaboration with privately held Dayra Therapeutics to discover and develop oral macrocyclic peptides for targets in immunological conditions. Biogen on Monday said it ...